| A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost … YF Chen, P Jobanputra, P Barton, S Jowett, S Bryan, W Clark, A Fry-Smith, ... Health technology assessment (Winchester, England) 10 (42), iii-iv, xi, 2006 | 550 | 2006 |
| Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and … YF Chen, P Jobanputra, P Barton, S Bryan, A Fry-Smith, G Harris, ... Health Technology Assessment (Winchester, England) 12 (11), 1-278, iii, 2008 | 480 | 2008 |
| Validity of Euroqol—A generic health status instrument—In patients with rheumatoid arthritis: Economic and Health Outcomes Research Group NP Hurst, P Jobanputra, M Hunter, M Lambert, A Lochhead, H Brown Oxford University Press 33 (7), 655-662, 1994 | 338 | 1994 |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic … K Malottki, P Barton, A Tsourapas, AO Uthman, Z Liu, K Routh, ... NIHR Health Technology Assessment programme: Executive Summaries, 2011 | 313 | 2011 |
| Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis A Filer, P De Pablo, G Allen, P Nightingale, A Jordan, P Jobanputra, ... Annals of the rheumatic diseases 70 (3), 500-507, 2011 | 273 | 2011 |
| Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology … MM Soliman, DM Ashcroft, KD Watson, M Lunt, DPM Symmons, KL Hyrich Annals of the rheumatic diseases 70 (4), 583-589, 2011 | 264 | 2011 |
| Effects of intermittent pressure-induced strain on the electrophysiology of cultured human chondrocytes: evidence for the presence of stretch-activated membrane ion channels. M Wright, P Jobanputra, C Bavington, DM Salter, G Nuki Clinical science (London, England: 1979) 90 (1), 61-71, 1996 | 237 | 1996 |
| Hyperpolarisation of cultured human chondrocytes following cyclical pressure‐induced strain: evidence of a role for α5β1 integrin as a chondrocyte mechanoreceptor MO Wright, K Nishida, C Bavington, JL Godolphin, E Dunne, S Walmsley, ... Journal of orthopaedic research 15 (5), 742-747, 1997 | 226 | 1997 |
| Clinical and cost-effectiveness of autologous chondrocyte implantation for cartilage defects in knee joints: systematic review and economic evaluation C Clar, E Cummins, L McIntyre, S Thomas, J Lamb, L Bain, P Jobanputra, ... Health technology assessment 9 (7), 2005 | 222 | 2005 |
| A pragmatic randomised controlled trial of hydrotherapy and land exercises on overall well being and quality of life in rheumatoid arthritis L Eversden, F Maggs, P Nightingale, P Jobanputra BMC musculoskeletal disorders 8, 1-7, 2007 | 190 | 2007 |
| Certolizumab pegol (CDP870) for rheumatoid arthritis in adults VR Garcia, A Burls, JB Cabello, PV Casasempere, S Bort‐Marti, JA Bernal Cochrane database of systematic reviews, 2017 | 152 | 2017 |
| The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. P Barton, P Jobanputra, J Wilson, S Bryan, A Burls Health Technology Assessment (Winchester, England) 8 (11), iii, 1-91, 2004 | 146 | 2004 |
| The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation P Jobanputra, P Barton, S Bryan, A Burls Health Technol Assess 6 (21), 1-110, 2002 | 145 | 2002 |
| Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) AL Herrick, X Pan, S Peytrignet, M Lunt, R Hesselstrand, L Mouthon, ... Annals of the rheumatic diseases 76 (7), 1207-1218, 2017 | 144 | 2017 |
| The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. W Clark, P Jobanputra, P Barton, A Burls Health Technology Assessment (Winchester, England) 8 (18), iii-iv, ix, 2004 | 112 | 2004 |
| Clinical utility of random anti–tumor necrosis factor drug–level testing and measurement of antidrug antibodies on the long‐term treatment response in rheumatoid arthritis M Jani, H Chinoy, RB Warren, CEM Griffiths, D Plant, B Fu, AW Morgan, ... Arthritis & rheumatology 67 (8), 2011-2019, 2015 | 110 | 2015 |
| A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis P Jobanputra, J Wilson, K Douglas, A Burls Rheumatology 43 (2), 206-210, 2004 | 96 | 2004 |
| Foot orthoses for patellofemoral pain in adults M Hossain, P Alexander, A Burls, P Jobanputra Cochrane database of systematic reviews, 2011 | 71 | 2011 |
| Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events P Jobanputra, R Amarasena, F Maggs, D Homer, S Bowman, E Rankin, ... BMC musculoskeletal disorders 9, 1-7, 2008 | 69 | 2008 |
| Providing patients with information about disease‐modifying anti‐rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and … D Homer, P Nightingale, P Jobanputra Musculoskeletal care 7 (2), 78-92, 2009 | 63 | 2009 |
